Pharma Marketing Network

According to Cegedim Strategic Data (CSD) -- a provider of healthcare promotional audits -- in the last 6 months of 2013, the global pharma...

In February 2014, FDA released a new draft guidance document entitled "Distributing Scientific and Medical Publications on Unapproved New Uses - Recommended Practices." FDA's...

"Not all available market research is created equal," says Rich Meyer, author of DTC Marketing Blog. According to Meyer, "some research is a must...

This article reviews BI's 'playbook' -- titled 'How pharma TweetChats can drive healthcare innovation' -- which provides detailed insights for planning and delivering successful pharma TweetChats. The authors of the playbook -- Patricia Alves, Social Media Community Manager, and Jaclyn Fonteyne, Social Media Specialist, at BI -- were also interviewed for this article.

This article reviews the FDA's guidance on how pharmaceutical companies can respond to misinformation related to a firm's own FDA-approved or -cleared products when that information is created or disseminated by independent third parties on the Internet or through social media, regardless of whether that misinformation appears on a firm's own forum or an independent third-party forum or website.

This article reviews the FDA's guidance on how pharma marketers must present both benefit and risk information within a

PMN1306-01Issue: Vol. 13, No. 6: June 2014Find other articles in related Topic Areas: eMarketing and ePromotionDirect-to-Consumer (DTC) Advertising & MarketingRegulatory Compliance

Welcome to Volume 13, Issue #6 (June 2014) of Pharma Marketing News.

I came upon an interesting chart in Mary Meeker’s state-of-the-Internet slide deck. Meeker — formerly of Morgan Stanley, at VC firm Kleiner Perkins since...

How should you name a new drug product? "That question," reports Alexander Gaffney (here), "is the subject of a new draft guidance by the...